Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

Pier Franco Conte, Andreas Schneeweiss, Sibylle Loibl, Eleftherios P. Mamounas, Gunter von Minckwitz, Max S. Mano, Michael Untch, Chiun Sheng Huang, Norman Wolmark, Priya Rastogi, Veronique D’Hondt, Andrés Redondo, Ljiljana Stamatovic, Hervé Bonnefoi, Hugo Castro-Salguero, Hans H. Fischer, Tanya Wahl, Chunyan Song, Thomas Boulet, Peter TraskCharles E. Geyer

Research output: Contribution to journalArticle

3 Scopus citations

Fingerprint Dive into the research topics of 'Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences